Blog
RSS FeedPosted by Michael Wonder on 06 Nov 2020
Brilinta approved in the US to reduce the risk of stroke in patients with an acute ischaemic stroke or high-risk transient ischaemic attack
6 November 2020 - New indication expands use of Brilinta beyond cardiovascular disease to patients with mild-to-moderate stroke ...
Posted by Michael Wonder on 06 Nov 2020
Xtandi (enzalutamide soft capsules) approved by China NMPA for the treatment of non-metastatic castration-resistant prostate cancer
6 November 2020 - Enzalutamide is now NMPA approved for both non-metastatic and metastatic castration-resistant prostate cancer. ...
Posted by Michael Wonder on 06 Nov 2020
New drug for gastro-intestinal stromal tumours to be launched in Australia, New Zealand and South East Asia following distribution agreement
5 November 2020 - Qinlock is already approved by the TGA and US FDA. ...
Posted by Michael Wonder on 06 Nov 2020
Genmab announces that Janssen has submitted a Type II variation application to the European Medicines Agency for use of subcutaneous Darzalex (daratumumab) in patients with light-chain amyloidosis
5 November 2020 - Submission is based on data from the Phase 3 ANDROMEDA (AMY3001) trial. ...
Posted by Michael Wonder on 05 Nov 2020
Pharma may avoid worst-case drug pricing scenario as US elections deadlocked
5 November 2020 - Pharma may have avoided a worst case scenario amid the political upheavals in the US elections ...
Posted by Michael Wonder on 05 Nov 2020
Cost effectiveness of cancer drugs: comparative analysis of the United States and England
5 November 2020 - England's National Institute for Health and Care Excellence and the US’ Institute for Clinical and Economic Review ...
Posted by Michael Wonder on 05 Nov 2020
Skin cancer drug not cost effective for routine NHS use
5 November 2020 - A consultation on the draft recommendations has now begun until Tuesday 24 November 2020. ...
Posted by Michael Wonder on 05 Nov 2020
Vertex announces European Commission approval for Kalydeco (ivacaftor) as first and only CFTR modulator to treat eligible infants with cystic fibrosis as early as four months of age
5 November 2020 - Approval provides opportunity to treat the underlying cause of cystic fibrosis earlier than ever before in Europe. ...
Posted by Michael Wonder on 05 Nov 2020
Lynparza approved in the EU as first-line maintenance treatment with bevacizumab for HRD positive advanced ovarian cancer
5 November 2020 - Patients treated with Lynparza and bevacizumab lived without disease progression for a median of 37.2 months vs. ...
Posted by Michael Wonder on 05 Nov 2020
Lynparza approved in the EU for the treatment of BRCA mutated metastatic castration-resistant prostate cancer
5 November 2020 - Only PARP inhibitor to improve overall survival versus new hormonal agent treatments in BRCA mutated metastatic ...
Posted by Michael Wonder on 05 Nov 2020
Forxiga approved in the EU for heart failure
5 November 2020 - Forxiga is the first SGLT2 inhibitor approved in the EU for heart failure with reduced ejection ...
Posted by Michael Wonder on 05 Nov 2020
Alberta, Canada sees early success from switching patients to biosimilars
5 November 2020 - Following the launch of its Biosimilars Initiative in December 2019, Alberta, Canada, has succeeded in switching 16% ...
Posted by Michael Wonder on 05 Nov 2020
Sobi launch Doptelet (avatrombopag) in Europe
4 November 2020 - Sobi today announced the commercial launch of Doptelet (avatrombopag) in Europe, with the United Kingdom as ...
Posted by Michael Wonder on 04 Nov 2020
Update on proposal to fund two new medicines for type 2 diabetes mellitus
5 November 2020 - PHARMAC would like to thank everyone who provided feedback on a proposal to fund two new medicines, ...
Posted by Michael Wonder on 04 Nov 2020
NICE updates guidance for nivolumab for melanoma
4 November 2020 - NICE has updated its guidance for nivolumab for adjuvant treatment of completely resected melanoma with lymph ...